Entering text into the input field will update the search result below

Hutchmed gets approval to market Elunate for colorectal cancer in Macau

Mar. 01, 2022 6:05 AM ETHUTCHMED (China) Limited (HCM)By: Ravikash, SA News Editor

Macau China

Sean Pavone/iStock via Getty Images

  • Hutchmed (China) (NASDAQ:HCM) received approval to market fruquintinib (sold as Elunate in China) to treat metastatic colorectal cancer in the Macau Special Administrative Region.
  • The approval follows the latest update to the provisions on new drug importation which allows

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About HCM

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
HUTCHMED (China) Limited
Axsome Therapeutics, Inc.
Organon & Co.
Prestige Consumer Healthcare Inc.
Amphastar Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.